Partnership Forum: The purpose of the forum was to identify concerns for high-investment medications related to predictability, affordability, and accessibility. Participants also explored alternative payments, financial tools, and policy initiatives related to these medications.

The purpose of this group is to continue the work of the previous groups and focus on collecting and disseminating guidelines for managed care pharmacists regarding integrated care models and benefit designs that effectively address substance use disorder.

Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.

Immunoglobulin (IG) derived from the plasma of donors is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders. To understand the appropriate and cost effective use of immunoglobulin, AMCP convened an expert panel of managed care stakeholders.

Partnership Forum: This forum identified challenges and payer needs related to the evidence for digital therapeutics. The forum explored the current market space for digital therapeutics including the evidence for the products, place in therapy, monitoring or utilization metrics and barriers that patients face in obtaining therapies.

AMCP will occasionally publish highlights from AMCP and other conferences designed for those in managed care pharmacy. Highlights include summaries of select featured session and posters. Meetings published currently include the AMCP Nexus 2021, NAMP 2021 Fall Managed Care Forum, American College of Rheumatologists Convergence 2021, and the 63rd ASH Annual Meeting & Exposition.

Partnership Forum: Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. This forum helped identify potential structural issues within the current formulary and benefit design processes that may have led to racial health disparities or inequality.